vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and AMPCO PITTSBURGH CORP (AP). Click either name above to swap in a different company.
AMPCO PITTSBURGH CORP is the larger business by last-quarter revenue ($104.4M vs $71.7M, roughly 1.5× Adaptive Biotechnologies Corp). Adaptive Biotechnologies Corp runs the higher net margin — -18.9% vs -55.2%, a 36.3% gap on every dollar of revenue. On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (51.0% vs 11.5%). Adaptive Biotechnologies Corp produced more free cash flow last quarter ($1.4M vs $-64.0K). Over the past eight quarters, Adaptive Biotechnologies Corp's revenue compounded faster (30.8% CAGR vs -2.6%).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
Ampco-Pittsburgh Corporation is a specialty steel manufacturer headquartered in Downtown Pittsburgh, Pennsylvania. It is one of several companies to bear the Ampco name, and it should not be confused with the Milwaukee-based copper base alloy producer, Ampco Metal Inc.; the Miami-based cabinetry company; the Swiss aluminum corporation; or the Dallas-based tool company. Ampco was formed in 1929 and is a conglomerate made up of several previously established small steel makers. Five small compa...
ADPT vs AP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $71.7M | $104.4M |
| Net Profit | $-13.6M | $-57.7M |
| Gross Margin | 74.6% | — |
| Operating Margin | -17.8% | -54.0% |
| Net Margin | -18.9% | -55.2% |
| Revenue YoY | 51.0% | 11.5% |
| Net Profit YoY | 59.7% | -1958.9% |
| EPS (diluted) | $-0.08 | $-2.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.7M | $104.4M | ||
| Q3 25 | $94.0M | $103.7M | ||
| Q2 25 | $58.9M | $108.9M | ||
| Q1 25 | $52.4M | $99.2M | ||
| Q4 24 | $47.5M | $93.6M | ||
| Q3 24 | $46.4M | $92.1M | ||
| Q2 24 | $43.2M | $107.1M | ||
| Q1 24 | $41.9M | $110.0M |
| Q4 25 | $-13.6M | $-57.7M | ||
| Q3 25 | $9.5M | $-2.2M | ||
| Q2 25 | $-25.6M | $-7.3M | ||
| Q1 25 | $-29.9M | $1.1M | ||
| Q4 24 | $-33.7M | $3.1M | ||
| Q3 24 | $-32.1M | $-2.0M | ||
| Q2 24 | $-46.2M | $2.0M | ||
| Q1 24 | $-47.5M | $-2.7M |
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 56.9% | — |
| Q4 25 | -17.8% | -54.0% | ||
| Q3 25 | 10.9% | 1.1% | ||
| Q2 25 | -42.5% | -2.8% | ||
| Q1 25 | -56.4% | 3.9% | ||
| Q4 24 | -71.3% | 5.5% | ||
| Q3 24 | -70.3% | 2.0% | ||
| Q2 24 | -109.6% | 4.7% | ||
| Q1 24 | -116.5% | 0.1% |
| Q4 25 | -18.9% | -55.2% | ||
| Q3 25 | 10.2% | -2.1% | ||
| Q2 25 | -43.5% | -6.7% | ||
| Q1 25 | -56.9% | 1.2% | ||
| Q4 24 | -71.0% | 3.3% | ||
| Q3 24 | -69.1% | -2.1% | ||
| Q2 24 | -107.0% | 1.9% | ||
| Q1 24 | -113.5% | -2.5% |
| Q4 25 | $-0.08 | $-2.87 | ||
| Q3 25 | $0.06 | $-0.11 | ||
| Q2 25 | $-0.17 | $-0.36 | ||
| Q1 25 | $-0.20 | $0.06 | ||
| Q4 24 | $-0.22 | $0.16 | ||
| Q3 24 | $-0.22 | $-0.10 | ||
| Q2 24 | $-0.31 | $0.10 | ||
| Q1 24 | $-0.33 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $70.5M | $10.7M |
| Total DebtLower is stronger | — | $117.9M |
| Stockholders' EquityBook value | $218.8M | $32.6M |
| Total Assets | $512.7M | $495.4M |
| Debt / EquityLower = less leverage | — | 3.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.5M | $10.7M | ||
| Q3 25 | $55.0M | $15.0M | ||
| Q2 25 | $43.2M | $9.9M | ||
| Q1 25 | $50.6M | $7.1M | ||
| Q4 24 | $47.9M | $15.4M | ||
| Q3 24 | $38.1M | $11.8M | ||
| Q2 24 | $59.8M | $7.9M | ||
| Q1 24 | $71.2M | $10.8M |
| Q4 25 | — | $117.9M | ||
| Q3 25 | — | $119.0M | ||
| Q2 25 | — | $115.9M | ||
| Q1 25 | — | $115.0M | ||
| Q4 24 | — | $116.4M | ||
| Q3 24 | — | $116.0M | ||
| Q2 24 | — | $119.4M | ||
| Q1 24 | — | $116.2M |
| Q4 25 | $218.8M | $32.6M | ||
| Q3 25 | $204.4M | $60.1M | ||
| Q2 25 | $179.7M | $62.7M | ||
| Q1 25 | $190.4M | $64.6M | ||
| Q4 24 | $202.7M | $58.9M | ||
| Q3 24 | $223.8M | $61.3M | ||
| Q2 24 | $241.6M | $58.0M | ||
| Q1 24 | $274.9M | $56.3M |
| Q4 25 | $512.7M | $495.4M | ||
| Q3 25 | $490.6M | $524.4M | ||
| Q2 25 | $496.6M | $537.2M | ||
| Q1 25 | $510.9M | $536.2M | ||
| Q4 24 | $539.4M | $530.9M | ||
| Q3 24 | $558.5M | $547.4M | ||
| Q2 24 | $584.9M | $560.8M | ||
| Q1 24 | $620.3M | $565.8M |
| Q4 25 | — | 3.61× | ||
| Q3 25 | — | 1.98× | ||
| Q2 25 | — | 1.85× | ||
| Q1 25 | — | 1.78× | ||
| Q4 24 | — | 1.98× | ||
| Q3 24 | — | 1.89× | ||
| Q2 24 | — | 2.06× | ||
| Q1 24 | — | 2.06× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.1M | $2.7M |
| Free Cash FlowOCF − Capex | $1.4M | $-64.0K |
| FCF MarginFCF / Revenue | 2.0% | -0.1% |
| Capex IntensityCapex / Revenue | 0.9% | 2.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-48.9M | $-8.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | $2.7M | ||
| Q3 25 | $-7.1M | $6.3M | ||
| Q2 25 | $-12.4M | $-2.3M | ||
| Q1 25 | $-28.5M | $-5.3M | ||
| Q4 24 | $-12.5M | $7.5M | ||
| Q3 24 | $-27.1M | $11.4M | ||
| Q2 24 | $-17.3M | $-5.3M | ||
| Q1 24 | $-38.4M | $4.5M |
| Q4 25 | $1.4M | $-64.0K | ||
| Q3 25 | $-7.5M | $3.3M | ||
| Q2 25 | $-13.1M | $-3.8M | ||
| Q1 25 | $-29.7M | $-7.5M | ||
| Q4 24 | $-12.6M | $3.7M | ||
| Q3 24 | $-27.4M | $8.4M | ||
| Q2 24 | $-19.0M | $-8.0M | ||
| Q1 24 | $-39.9M | $1.7M |
| Q4 25 | 2.0% | -0.1% | ||
| Q3 25 | -8.0% | 3.2% | ||
| Q2 25 | -22.2% | -3.5% | ||
| Q1 25 | -56.7% | -7.5% | ||
| Q4 24 | -26.5% | 4.0% | ||
| Q3 24 | -59.0% | 9.1% | ||
| Q2 24 | -44.1% | -7.5% | ||
| Q1 24 | -95.2% | 1.5% |
| Q4 25 | 0.9% | 2.7% | ||
| Q3 25 | 0.4% | 2.9% | ||
| Q2 25 | 1.1% | 1.3% | ||
| Q1 25 | 2.4% | 2.2% | ||
| Q4 24 | 0.2% | 4.0% | ||
| Q3 24 | 0.7% | 3.2% | ||
| Q2 24 | 4.0% | 2.5% | ||
| Q1 24 | 3.6% | 2.6% |
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -4.62× | ||
| Q4 24 | — | 2.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.64× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
AP
| Forged And Cast Mill Rolls | $67.0M | 64% |
| Air Handling Systems | $14.3M | 14% |
| Heat Exchange Coils | $13.1M | 13% |
| Centrifugal Pumps | $10.3M | 10% |
| Forged Engineered Products | $4.0M | 4% |
